Home
Search:
1146 feeds
357 categories
6141 articles (<24 hours)
15 registered users

Use the Mobile version
Mobile

Follow our Twitter feed

View our Linkpartners
Links

Username:
Password:

Register | Retrieve

Science


Valid HTML 4.01 Transitional

RSS FeedsMitsubishi Tanabe Pharma Corporation Announces Results of the MT-7117 ENDEAVOR Study for the Ultra-Rare Disease, Erythropoietic Protoporphyria (EPP)
(WorldNews Health)

 
 

11 november 2019 04:20:53

 
Mitsubishi Tanabe Pharma Corporation Announces Results of the MT-7117 ENDEAVOR Study for the Ultra-Rare Disease, Erythropoietic Protoporphyria (EPP)
(WorldNews Health)
 




November 11, 2019 Mitsubishi Tanabe Pharma Corporation Announces Results of the MT-7117 ENDEAVOR Study for the Ultra-Rare Disease, Erythropoietic Protoporphyria (EPP) Mitsubishi Tanabe Pharma Corporation (MTPC) announces successful completion of the ENDEAVOR study for MT-7117 (dersimelagon - selective MC1R agonist), an investigational oral treatment under development by Mitsubishi Tanabe Pharma Development America, Inc. (MTDA) for the prevention of phototoxicity (including severe pain on exposure to sunlight) in patients with erythropoietic protoporphyria (EPP).1 ENDEAVOR is a phase 2 proof of concept study for MT-7117 as a treatment option for EPP. ENDEAVOR met its primary endpoint of...
 
17 viewsCategory: Science > Medicine
 
AAMC leaders issue call to action to confront challenges facing academic medicine
(WorldNews Health)
HIF-PH Inhibitor Vadadustat (MT-6548) Japan Phase 3 results for the treatment of renal anemia at American Society of Nephrology, Kidney Week 2019
(WorldNews Health)
 
 
blog comments powered by Disqus


Copyright © 2008 - 2019 Indigonet Services B.V.. Contact: Tim Hulsen. Read here our privacy notice.
Other websites of Indigonet Services B.V.: Nieuws Vacatures Science Tweets Travel Photos Nachrichten Indigonet Finances Leer Mandarijn